Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised

Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.

Abstract

Objective: The aim of the present study is to examine the accuracy of the Brazilian versions of the Montreal Cognitive Assessment (MoCA) and the Addenbrooke's Cognitive Examination-Revised (ACE-R) to screen for mild cognitive impairment (PDMCI) and dementia (PDD) in patients with Parkinson's disease (PD).

Method: Both scales were administered to a final convenience sample of 79 patients with PD. Patients were evaluated by a neurologist, a psychiatrist and a neuropsychologist using UPDRS, Hoehn and Yahr and Schwab and England scales, global deterioration scale, a psychiatric structured interview, Mattis Dementia Rating Scale and other cognitive tests.

Results: There were 32 patients with PDMCI and 17 patients with PDD. The MoCA and the ACE-R were able to discriminate patients with PDD from the others.

Conclusion: Both scales showed to be useful to screen for dementia but not for mild cognitive impairment in patients with PD.

Publication types

  • Evaluation Study
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brazil
  • Cognitive Dysfunction / diagnosis*
  • Cognitive Dysfunction / physiopathology
  • Dementia / diagnosis*
  • Dementia / physiopathology
  • Epidemiologic Methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests / standards*
  • Parkinson Disease / complications*
  • Parkinson Disease / physiopathology
  • Psychiatric Status Rating Scales / standards*
  • Reproducibility of Results